Anti-CD64-anti-CD30 bispecific monoclonal antibody (Medarex)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD64-anti-CD30 bispecific monoclonal antibody (Medarex)

Drug Alias NameH22xKi-4

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitorsHigh affinity immunoglobulin gamma Fc receptor I antagonists

TargetsTumor necrosis factor receptor superfamily member 8High affinity immunoglobulin gamma Fc receptor I

Therapy Area/IndicationsHodgkin Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMedarex Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedarex Inc

Active IndicationsN/A

Inactive IndicationsHodgkin Disease

Other Information

ATC CodeN/A